Eric Van Cutsem

184.6k citations
1.1k papers · 138.6k · 80 hit papers · h-index 165

Impact in

  • Oncology top 0.01%
    • Colorectal Cancer Treatments and Studies
    • Cancer Immunotherapy and Biomarkers
    • Pancreatic and Hepatic Oncology Research
    • Colorectal Cancer Surgical Treatments
    • Gastric Cancer Management and Outcomes

Papers in

    • Colorectal Cancer Treatments and Studies 487
    • Colorectal Cancer Surgical Treatments 89
    • Pancreatic and Hepatic Oncology Research 81
    • Cancer Immunotherapy and Biomarkers 64
    • Gastric Cancer Management and Outcomes 159

Eric Van Cutsem

1.1k papers receiving 134.8k citations

Eric Van Cutsem's Hit Papers

Tucatinib plus trastuzumab for chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer (MOUNTAINEER): a multicentre, open-label, phase 2 study 2023 · 183 citations
1830+1+3Years since publication100200300400500

Peers

Eric Van Cutsem
Comparison fields: 5 of 181
  • Oncology 75.2k
  • Pulmonary and Respiratory Medicine 21.1k
  • Cancer Research 6.5k
  • Hepatology 3.4k
  • Pathology and Forensic Medicine 5.2k
Replace Leonard B. Saltz with:
Leonard B. Saltz United States
David Cunningham United Kingdom
Jedd D. Wolchok United States
Josep M. Tabernero Spain
Daniel J. Sargent United States
Jaap Verweij Netherlands
Frank Stephen Hodi United States
José Baselga United States
Al B. Benson United States
Caroline Robert France
Eric Van Cutsem relative to Leonard B. Saltz United States Leonard B. Saltz's profile →
Citations per field
00.5×2×3×4.0×
Leonard B. Saltz · 1×
Citations per year

Countries citing papers authored by Eric Van Cutsem

Since Specialization
Citations

This map shows the geographic impact of Eric Van Cutsem's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Eric Van Cutsem with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Eric Van Cutsem more than expected).

Fields of papers citing papers by Eric Van Cutsem

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Eric Van Cutsem. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Eric Van Cutsem. The network helps show where Eric Van Cutsem may publish in the future.

Co-authors

The 25 scholars most cited alongside Eric Van Cutsem, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Eric Van Cutsem Line = papers co-authored together Eric Van Cutsem links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 1.1k papers — load more, or switch the sort, to bring in the rest.

#Work
1
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
Hit paper breakdown →
20105931
2
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
Hit paper breakdown →
20135386
3
Cetuximab Monotherapy and Cetuximab plus Irinotecan in Irinotecan-Refractory Metastatic Colorectal Cancer
Hit paper breakdown →
20044187
4
Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer
Hit paper breakdown →
20093202
5
Wild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer
Hit paper breakdown →
20082685
6
ESMO consensus guidelines for the management of patients with metastatic colorectal cancer
Hit paper breakdown →
20162685
7
Phase 3 Trial of 177 Lu-Dotatate for Midgut Neuroendocrine Tumors
Hit paper breakdown →
20172540
8
Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial
Hit paper breakdown →
20122366
9
Everolimus for Advanced Pancreatic Neuroendocrine Tumors
Hit paper breakdown →
20112355
10
Pembrolizumab in Microsatellite-Instability–High Advanced Colorectal Cancer
Hit paper breakdown →
20202187
11
Sunitinib Malate for the Treatment of Pancreatic Neuroendocrine Tumors
Hit paper breakdown →
20112044
12
Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial
Hit paper breakdown →
20141968
13
Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis
Hit paper breakdown →
20101821
14
Maintenance Olaparib for Germline BRCA -Mutated Metastatic Pancreatic Cancer
Hit paper breakdown →
20191784
15
Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair–Deficient/Microsatellite Instability–High Metastatic Colorectal Cancer
Hit paper breakdown →
20181691
16
Open-Label Phase III Trial of Panitumumab Plus Best Supportive Care Compared With Best Supportive Care Alone in Patients With Chemotherapy-Refractory Metastatic Colorectal Cancer
Hit paper breakdown →
20071650
17
Phase III Study of Docetaxel and Cisplatin Plus Fluorouracil Compared With Cisplatin and Fluorouracil As First-Line Therapy for Advanced Gastric Cancer: A Report of the V325 Study Group
Hit paper breakdown →
20061619
18
Cetuximab Plus Irinotecan, Fluorouracil, and Leucovorin As First-Line Treatment for Metastatic Colorectal Cancer: Updated Analysis of Overall Survival According to Tumor KRAS and BRAF Mutation Status
Hit paper breakdown →
20111596
19
Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial
Hit paper breakdown →
20081539
20
Gastric cancer
Hit paper breakdown →
20161524

About Eric Van Cutsem

Eric Van Cutsem is a scholar working on Oncology, Pulmonary and Respiratory Medicine, Epidemiology, Pathology and Forensic Medicine and Hepatology, having authored 1.1k papers that have together received 138.6k indexed citations. Recurring topics across this work include Colorectal Cancer Treatments and Studies (487 papers), Gastric Cancer Management and Outcomes (159 papers), Colorectal Cancer Surgical Treatments (89 papers), Pancreatic and Hepatic Oncology Research (81 papers), Neuroendocrine Tumor Research Advances (74 papers), Cancer Immunotherapy and Biomarkers (64 papers), Esophageal Cancer Research and Treatment (47 papers) and Genetic factors in colorectal cancer (41 papers). The work is most often cited by research in Oncology (75.2k citations), Pulmonary and Respiratory Medicine (21.1k citations), Cancer Research (6.5k citations), Hepatology (3.4k citations) and Pathology and Forensic Medicine (5.2k citations). Eric Van Cutsem has collaborated with scholars based in Belgium, United States and Spain. Frequent co-authors include Philippe R Rougier, Sabine Tejpar, Josep M. Tabernero, Salvatore Siena, Marc Peeters, David Cunningham, Bernard Nordlinger, Yves Humblet, Atsushi Ohtsu and Chris Verslype. Their work appears in journals such as Annals of Oncology, Journal of Clinical Oncology, European Journal of Cancer, The Lancet Oncology and ESMO Open.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact